ATAD2 was investigated to be highly expressed in renal cancer, and ATAD2 serves as a target of miR-372 directly in renal cancer cell lines and is regulated negatively by miR-372, which in turn affects cancer cell invasion, metastasis, and EMT function. Here, ATAD2 is linked to renal carcinoma.